🎉 Health Canada Provides a No Objection Letter for ATMA’s N500 Phase II Clinical Trial Application

Day: September 7, 2022

Psychedelic Breakthrough

Breakthroughs in the Therapy Room – Hope for Treatment Resistant Mental Illness?

By Rachel Dundas, Registered Psychologist Certified Trauma Practitioner What does it mean to be an effective therapist? Surely, most new graduates are entering the therapy profession with energy, enthusiasm, and aspirations to support and empower their clientele. Intentions, however, do not always translate to therapeutic effectiveness. Does being an effective therapist mean you have a …

Breakthroughs in the Therapy Room – Hope for Treatment Resistant Mental Illness? Read More »

ATMA Journey Centers observes positive outcomes from a Phase I clinical trial of psilocybin in healthy participants

Fourteen healthy subjects completed an experiential session after receiving 25 mg psilocybin  – Results of this phase I study will inform the design of Phase II study in frontline healthcare workers, examining the efficacy of psilocybin for Covid-related stress. Calgary, September 7, 2022 — ATMA Journey Centers (the “Company”), a company providing therapist training and support, has …

ATMA Journey Centers observes positive outcomes from a Phase I clinical trial of psilocybin in healthy participants Read More »

Scroll to Top